BTG.L - BTG plc

LSE - LSE Delayed price. Currency in GBp
751.00
-9.00 (-1.18%)
At close: 5:02PM BST
Stock chart is not supported by your current browser
Previous close760.00
Open762.50
Bid650.00 x 66000
Ask0.00 x 112600
Day's range748.50 - 764.58
52-week range528.36 - 764.58
Volume566,556
Avg. volume492,363
Market cap2.9B
Beta0.15
PE ratio (TTM)87.33
EPS (TTM)8.6
Earnings date14 Nov 2017
Forward Dividend & YieldN/A (N/A)
Ex-dividend dateN/A
1y target est775.33
  • Fool.co.ukyesterday

    2 pharma stocks that could make you a millionaire

    The FTSE 100 isn’t the last word for great pharmaceutical stocks. Here, Royston Wild looks at two medical marvels outside of the blue-chip index.

  • Market Realist4 days ago

    Reading the Drop in Precious Metals on Monday, October 16

    After the rise we saw on Friday, October 13, precious metals had a down day on Monday, October 16.

  • Fool.co.uk4 days ago

    A growth stock I’d buy alongside this Neil Woodford favourite

    Top investor Neil Woodford has a nose for major growth stocks, and you can follow his lead.

  • Market Realist11 days ago

    How Miners’ Correlations with Gold in the Past Year Have Trended

    On a YTD basis, First Majestic has the lowest correlation to gold, while Primero Mining has the highest correlation to gold.

  • PR Newswire14 days ago

    First Patient Treated With Microscopic Beads Pre-loaded With a Targeted Cancer Drug and Visible on CT Scans

    Researchers from the UCL Cancer Institute and the specialist healthcare company BTG plc (BTG.L) have begun the first clinical trial of an experimental treatment for liver cancer using X-ray imageable microscopic beads loaded with a targeted anti-cancer drug placed directly in the liver. The trial will evaluate delivering a precisely controlled dose of vandetanib, an inhibitor of multiple tumour growth pathways, directly to the arteries feeding a liver tumour by pre-loading the drug on a radiopaque bead which can be visualised on CT scans. Although still at a very early stage of research, the development programme aims to improve current treatments for patients with primary liver cancer and metastatic Colorectal Cancer (mCRC).

  • Market Realist17 days ago

    How Mining Stocks Are Performing

    The precious metals continued rising on Wednesday, and gold also witnessed a rebound.

  • Market Realist17 days ago

    What Influences the Rise and Fall of Gold?

    If higher cash flows are offered on Treasuries, chances are that investors could switch to yield-bearing assets and desert precious metals.

  • Fool.co.uk17 days ago

    2 growth stocks I’d buy and hold for 25 years

    These two growth shares appear to have upside potential.

  • Reuters17 days ago

    BTG to buy Roxwood Medical for up to $80 million

    Roxwood's portfolio of anchoring catheters and microcatheters for treatment of complex cardiovascular lesions should leverage BTG's existing successful EKOS (endovascular system) sales and marketing operation, Deutsche Bank analysts said in a note. Separately, BTG stuck to its double-digit product sales growth forecast, adding that licensing revenue in the first half has benefited from back royalties on Lemtrada, Sanofi's (SASY.PA) multiple sclerosis treatment. BTG said licensing revenue is expected to decline over the full year by low double digits at constant currency, compared to a previous forecast of a high-teens decline.

  • Reuters - UK Focus17 days ago

    UK's BTG to buy Roxwood Medical for up to $80 mln

    British drugs company BTG Plc said on Thursday it will buy U.S.-based cardiovascular catheter maker Roxwood Medical for up to $80 million. The deal, which is expected to be accretive to adjusted profit ...

  • Market Realist19 days ago

    How Gold Reacts to the Stock Market

    Equities and safe-havens like gold are historically known to move in opposite directions because gold is often seen as a hedge against overall market risk.

  • Market Realist19 days ago

    Mining Stocks in 2017: Your Correlation Analysis

    Thursday, September 28, was a mixed day for precious metal mining stocks as precious metals (except platinum) saw marginal revivals in prices.

  • Fool.co.uk28 days ago

    3 stocks Neil Woodford should buy more of

    I believe that these three Neil Woodford stocks look undervalued.

  • Reuters - UK Focuslast month

    BTG ordered to pay damages of $55.8 mln to Wellstat

    British drugs company BTG has been ordered to pay damages of $55.8 million plus interest and costs to Wellstat Therapeutics in a dispute over the distribution of Vistogard, an antidote to the overdose of two chemotherapy drugs. BTG (Frankfurt: 908827 - news) said a court in Delaware had issued the ruling in a case concerning the commercialisation of Vistogard, finding that the British company had breached the distribution agreement. "BTG is surprised and disappointed by the opinion and is considering options, which include appealing the ruling and level of damages awarded," the company said on Wednesday.

  • Business Wire4 months ago

    ACCESS PTS Study Demonstrates Efficacy of EKOS® Therapy for Post-Thrombotic Syndrome

    BOTHELL, Wash.--(BUSINESSWIRE)-- BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the results of the ACCESS PTS trial , presented at the Society for Vascular Medicine 28 th ...

  • Reuters - UK Focus5 months ago

    Greek stocks rise as Eurogroup meets; Europe-U.S. M&A at decade high - For more see the European equities LiveMarkets blog

    Live coverage of European markets now available on cpurl://apps.cp./cms/?pageId=livemarkets Summary: ** Athens stocks up as euro zone finance ministers meet for Greek deal ** Clariant-Huntsman tie-up takes ...

  • Reuters - UK Focus5 months ago

    BTG's pulmonary embolism device work faster and at lower doses in study

    British pharmaceutical firm BTG said on Monday its EKOS combination therapy device for pulmonary embolism (PE) was effective using smaller drug dosages and shorter treatment periods than the current standard. EKOS, which the company says it the only device cleared to treat pulmonary embolism, uses ultrasonic waves and clot-dissolving thrombolytic drugs delivered by a catheter to restore healthy heart function and blood flow. BTG (Frankfurt: 908827 - news) 's shares were up 4 percent at 662 pence at 1137 GMT.

  • Reuters - UK Focus5 months ago

    Earnings drag on European shares, though Vodafone lifts telcos

    European shares ended little changed on Tuesday as disappointing earnings updates weighed on banks and pharma stocks, but a well-received outlook from Vodafone helped Britain's FTSE 100 touch a record high. Germany's DAX also hit a fresh all-time peak before reversing course to end flat.

  • Reuters - UK Focus5 months ago

    Vodafone powers Britain's FTSE to new record high

    Britain's main share index scaled yet another record high on Tuesday, scoring nine days of gains in a row, as Vodafone shares jumped after it forecast earnings growth ahead. The FTSE 100 ended up 0.9 percent, with telecoms stocks and consumer staples providing the impetus, while energy stocks supported gains as the price of crude rose.

  • Reuters - UK Focus5 months ago

    BTG shares hit as medical product outlook disappoints

    British healthcare group BTG disappointed investors on Tuesday with a slower-than-expected forecast for growth in its interventional medicine business, sending the shares nearly 10 percent lower. BTG - previously best known for drugs to treat overdoses and rattlesnake bites - has been reinventing itself in recent years by focusing on interventional medicine, in which image-guided devices are used to treat a range of diseases. For the current year, BTG (Frankfurt: 908827 - news) said interventional medicine would deliver mid-to-high teens percentage sales growth, at constant exchange rates (CER), well below the 26 percent that analysts at Jefferies said they had been forecasting.

  • Reuters - UK Focus5 months ago

    BTG shares slide as healthcare group's growth outlook disappoints

    British healthcare group BTG disappointed investors on Tuesday with a slower-than-expected forecast for growth in its interventional medicine business, sending the shares 8 percent lower in early trade. BTG - previously best known for drugs to treat overdoses and rattlesnake bites - has been reinventing itself in recent years by focusing on interventional medicine, in which image-guided devices are used to treat a range of diseases. For the current year, BTG (Frankfurt: 908827 - news) said interventional medicine would deliver mid-to-high teens percentage sales growth, at constant exchange rates (CER), well below the 26 percent that analysts at Jefferies said they had been forecasting.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes